Active substance
Cystagon is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.
Procysbi is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.
Cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 6 months of age with cystinosis.
Treatment of corneal cystine deposits
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| CYSTADROPS 3.8 MG/ML EYE DROPS SOLUTION | PLGB 15266/0021 | RECORDATI RARE DISEASES | POM |
| CYSTAGON 150 MG HARD CAPSULES | PLGB 15266/0022 | RECORDATI RARE DISEASES | POM |
| CYSTAGON 50 MG HARD CAPSULES | PLGB 15266/0023 | RECORDATI RARE DISEASES | POM |
| PROCYSBI 25 MG GASTRO-RESISTANT HARD CAPSULES | PLGB 08829/0190 | CHIESI LIMITED | POM |
| PROCYSBI 300MG GASTRO-RESISTANT GRANULES | PLGB 08829/0206 | CHIESI LIMITED | POM |
| PROCYSBI 75 MG GASTRO-RESISTANT HARD CAPSULES | PLGB 08829/0191 | CHIESI LIMITED | POM |
| PROCYSBI 75MG GASTRO-RESISTANT GRANULES | PLGB 08829/0205 | CHIESI LIMITED | POM |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Mercaptamine 150mg capsules | £190.00 | 100 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Mercaptamine 25mg gastro-resistant capsules | £335.97 | 60 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Mercaptamine 3.8mg/ml eye drops | £865.00 | 5 ml | 1 Oct 2026 |
| NHS Drug Tariff | Mercaptamine 50mg capsules | £70.00 | 100 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Mercaptamine 75mg gastro-resistant capsules | £4199.65 | 250 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.